One in three across the UK late to examine cervical cancer health
Experts have warned that a third of people across the United Kingdom have been late for examining cervical cancer, while in parts of England more vulnerable to the disease than others due to the low absorption of the preventive vaccine.
Since the Korona virus pandemic, a cervical examination rate has decreased for women and other people with the cervical steadily, from 72.2 % in 2020 to 68.4 % in 2024, as NHS England data appears.
The Yajov poll, which included 3000 people all over the UK qualified to examine cervical cancer, is composed by Cancer Research UK, with these results, as 30 % of the respondents are delayed in the examination.
It also highlighted the main barriers that people were martyred, as 42 % of the respondents found a painful cervical examination previously, and 40 % do not want a man to test the examination, and less than one in five (19 %) of the respondents, saying they were very embarrassing to go to a show.
Among those who did not attend their examination, 16 % of the respondents said that they had no symptoms – highlighting the wrong information is still prevalent in cervical examination, which is for people who have no symptoms.
Separate numbers from the UK Security Agency (UKHSA) found that the absorption of the HPV vaccine varies greatly by region, where girls in London enjoy the 10th year of the slightest absorption (64.9 %) and girls in the southeast above (82.7 %).
Among the boys of the same age, it was also the lowest level in London (58.9 %) and the highest in the southeast (77.3 %).
HPV refers to a group of viruses that can be transmitted through sexual communication and does not cause any symptoms. It is known that about 13 high -risk types of HPV causes 99.7 % of cervical cancers.
Every year, about 3,200 women in the UK are diagnosed with cervical cancer and 850 dies of them. This is the fourteenth of the most common cancer that affects women in Britain, where women from 30 to 34 are likely to receive diagnosis. Last year, NHS England pledged to survey cervical cancer by 2040.
Globally, it is the fourth most common cancer in women, with about 660,000 new cases and 350,000 deaths every year, according to the World Health Organization.
This disease develops when abnormal cells appear in the cervical lining and grow, ultimately together. If the cells are not arrested early, cancer can spread to other parts of the body.
In June, NHS England said that women between the ages of 25 and 49 and who are tested negatively for the HPV, which means that they are at risk of developing cervical cancer over the next ten years, will be safely invited at five -year periods instead of three.
Fiona Osgon, head of health information in cancer research in the United Kingdom, said that low prices were caused by a group of factors.
After promoting the newsletter
“We know that people have specific obstacles to access to the examination; some of them are practical such as the inability to get an appointment at a time when they are working, but some are more specific to the test itself, such as finding a painful examination or anxiety about who will do the test,” said Osgon.
“I think we have just seen a slow decrease, which can unfortunately happen even with successful examination programs.
“We need to continue to get rid of misunderstanding and misconceptions that some people have regard to cervical examination.”
Osgun added that there were various measures that people could request a more comfortable cervical test test, such as requesting a double date or diligently.
“The NHS HPV vaccination program has already helped to save thousands of lives, and we need to move forward to increase the absorption of human papillomas vaccines and cervical examination to help eliminate the cancer of the eruption in England by general solutions 2040. “